Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children
NCT: NCT07188779 · RECRUITING
Brief Summary
The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following pediatric tonsillectomy procedures. Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.Participants will: Undergo tonsillectomy procedure. Receive and fill out a survey sent via email every 2 days following their procedure for 15 days, plus an additional survey on day 30, and track their symptoms.
Frequently Asked Questions
What is Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children?
Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children is a clinical trial registered under NCT07188779. Current status: RECRUITING.
What is the status of NCT07188779?
The current status of NCT07188779 (Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children) is: RECRUITING.
When did Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children start?
Impact of RADA16 Use on Outcomes Following Tonsillectomy in Children started on 2026-05-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.